BioSpace News Archive

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce it dosed patients in a Phase I/II clinical trial, evaluating the safety and efficacy of its lead anti-infective candidate, RECCE® 327 (R327), for the treatment of diabetic foot infections (DFI).

aTyr Pharma, Inc. (Nasdaq: LIFE) today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will host a virtual key opinion leader (KOL) event on XTRAC® and TheraClear®X on Wednesday, September 20, 2023, at 10:00 AM – 12:00 PM ET.

Akeso Inc. announced today that the New Drug Application (NDA) for its fully human IgG1 monoclonal antibody, ebdarokimab (IL-12/lL-23, AK101) has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the People’s Republic of China (NMPA CDE) for the treatment of adult patients with moderate-to-severe plaque-type psoriasis.

Antheia announced the successful completion of its first 116,000L scale manufacturing run with a commercially-relevant fermentation titer for its debut product.

GE HealthCare, is announcing that members of its senior management team will be presenting at the following investor conferences next month.

Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm.

Fresenius Kabi and Lupagen Inc. announced the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification.

GE HealthCare announces the launch of CardioVisio for Atrial Fibrillation, a digital tool designed to assist clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources, and driving evidence based clinical decision support directed by up-to-date AFib guidelines.